ICON PLC (ICLR)
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Sector: Services-Commercial Physical & Biological Research
Industry: Medical - Diagnostics & Research
ICON Public Limited Company
Trials need funding. See this company's dilution risk and cash position.
- Phase 3Completed
The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
IBI-10090, Placebo
Inflammation, Cataracts
NCT02006888Enrollment394StartJan 2014Primary CompletionOct 2014CompletionOct 2014 - Phase 3Completed
Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery
Dexamethasone, Prednisolone
Cataract
NCT02547623Enrollment194StartNov 2015Primary CompletionAug 2016CompletionAug 2016 - Phase 2Terminated
Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery
IBI-10090
Inflammatory Reaction Due to Ocular Lens Prosthesis
NCT01048593Enrollment6StartJan 2010Primary CompletionMay 2010CompletionJun 2010 - Phase 2Terminated
Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients
IBI-10090
Ocular Inflammation
NCT01214174Enrollment42StartOct 2010Primary CompletionMay 2012CompletionMay 2012 - Phase 2Completed
Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
IBI-10090
Inflammation Associated With Cataract Surgery
NCT01606735Enrollment172StartApr 2012Primary CompletionMar 2013CompletionMar 2013
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 3 | Completed | IBI-10090, Placebo | NCT02006888 |
| Phase 3 | Completed | Dexamethasone, Prednisolone | NCT02547623 |
| Phase 2 | Terminated | IBI-10090 | NCT01048593 |
| Phase 2 | Terminated | IBI-10090 | NCT01214174 |
| Phase 2 | Completed | IBI-10090 | NCT01606735 |